COMPANY PROFILE

Kayentis

Explore full profile

Kayentis is a software provider specialized in clinical trials solutions

Meylan, FranceFounded 2004Health Tech & Medtech

Valuation $25–50M Last recorded · 2023

Revenue $10–50M Latest reported FY

Headcount 100–500 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Kayentis

Kayentis specializes in electronic Clinical Outcome Assessment (eCOA) solutions, focusing on improving data collection and patient engagement in clinical trials. The company serves pharmaceutical companies and clinical research organizations (CROs) by providing tools and services that ensure accurate, reliable, and complete data from patients. Operating in the global clinical trials market, Kayentis leverages over a decade of experience to offer tailored solutions that address cultural differences and specific trial requirements. The business model is service-based, generating revenue through the provision of eCOA platforms and associated support services. By enhancing patient compliance and engagement, Kayentis helps clients reduce trial costs and improve data quality.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2004
Headquarters: Meylan, France
Employees: 168
Open positions: 1
Dealroom signal: 37.7/100
Industry: Health, Enterprise Software
Sub-industry: Health Platform
Sector: Health Tech & Medtech, Risk Management, Clinical, Tech for Biotech and Pharma, Hard Tech, Digital Pharma, observatoire healthtech
Technology: Big Data
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBT✓Debt	Mar 2023	$3.1M	—	Undisclosed	↗
LATE VC✓Equity / VC	Mar 2023	$2.4M	$37M	Extens · Bpifrance · LBO France	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Kayentis website traffic

Latest recorded traffic for Kayentis is 2K monthly website visits, up 5.3% over the last three months. Kayentis's team grew 1.2% over the past year.

Latest monthly visits2K 3-month web change+5.3% 1-year team growth+1.2%

Monthly website visitsJun 2015–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NONovadiscoveryDe-risking technology provider specialized in in silico clinical trials supporting biotech and pharma companies	Lyon, France	Operational	63	$8.5M	$28M
INInatoAI-powered patient recruitment	Paris, France	Operational
PHPharmaforesight.aiDeveloped a powerful machine learning algorithm that can predict the probability of success of a trial, before it has even started	London, United Kingdom	Operational
APAriana PharmaPremium provider of advanced, clinical and biomarker data analytics technology	Paris, France	Operational
MEMedial EarlysignHealthcare company using AI to predict and prevent high-risk diseases	Kfar Malal, Israel	Operational
KLKlineoBridge the gap between patients and clinical research	Paris, France	Operational
TITriumph Research IntelligenceGlobal provider of Risk-Based Monitoring (RBM) solutions for clinical trials	London, United Kingdom	Operational
INInpartInpart (formerly Inova) is a SaaS platform that facilitates and manages scientific partnerships between industry and academia, particularly in the life sciences and biopharma sectors	Lyon, France	Operational